Furthermore, it has been reported that MLL and CBP, together with CREB or MYB, form a ternary complex in vitro, and inhibitors targeting the MYB:CBP/P300 complex are very efficient at suppressing the survival of leukaemia cells harbouring MLLr [38, 39]. Here, KMT2A is linked to leukemia.